

Subcommittee topics. The first panel will focus on the impact of Value-Based Purchasing Demonstrations. The second panel will focus on primary care training and placement. The Subcommittees will then move into breakout sessions to further discuss these topics. After the panel discussions, the Committee Chair will give an overview of the site visits. This will be followed by a call for public comment. The Wednesday meeting will close at 4:45 p.m.

Thursday morning, at 9 a.m., the Committee will travel to Munson Medical Center for a briefing on its role in serving the region. At 10 a.m. the Committee will break into Subcommittees and depart to the site visits. The Value-Based Purchasing Demonstrations Subcommittee will meet at Mercy Cadillac Hospital in Cadillac, MI. The Primary Care Training and Placement Subcommittee will meet at Kalkaska Rural Health Clinic in Kalkaska, MI. The Subcommittees will return to the Park Place Hotel in Traverse City at 4 p.m. Transportation to the site visits will not be provided to the public. The Thursday meeting will close at 4:45 p.m.

The Final session will be convened on Friday morning at 8:45 a.m. The meeting will open with a review of the Subcommittee site visits. The Committee will draft a letter to the Secretary or Designee and discuss the September 2011 meeting. The meeting will adjourn at 10:30 a.m.

For Further Information Contact: Thomas Morris, MPA, Executive Secretary, National Advisory Committee on Rural Health and Human Services, Health Resources and Services Administration, Parklawn Building, Room 10B-45, 5600 Fishers Lane, Rockville, MD 20857, Telephone (301) 443-0835, Fax (301) 443-2803.

Persons interested in attending any portion of the meeting should contact Deborah DeMasse-Snell at the Office of Rural Health Policy (ORHP) via Telephone at (301) 443-0835 or by e-mail at ddemasse-snell@hrsa.gov. The committee meeting agenda will be posted on ORHP's Web site <http://www.ruralhealth.hrsa.gov>.

Dated: April 28, 2011.

Reva Harris,

Acting Director, Division of Policy and Information Coordination.

[FR Doc. 2011-10983 Filed 5-4-11; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; *telephone:* 301-496-7057; *fax:* 301-402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Improved Standard for Immune System Recovery Assay

Description of Invention: Monitoring an immune system that has been depleted by infection (e.g., HIV), chemotherapy, or progenitor cell transplantation is vital to assessing individual's recovery status. This technology provides a new plasmid standard to be used as part of the existing TREC assay. This new plasmid has a shorter insert than the commercially available one, which means it now matches the PCR product generated in the qPCR reaction in the TREC assay. Additionally, the new plasmid is easier to grow up than the existing standard.

Applications: TREC assay for T-cell concentration measurements.

Advantages:

- The insert of standard plasmid is shorter and directly matches the PCR product generated in the qPCR reaction.
- The standard plasmid is easy to grow up.

Development Status: Fully developed.

Inventors: Daniel C. Douek, Richard A. Koup, Brenna J. Hill (NIAID.)

Relevant Publications:

1. Douek *et al.* Changes in thymic function with age and during the treatment of HIV infection. *Nature* 1998 Dec 17;396(6712):690-695. [*PubMed:* 9872319.]

2. Douek *et al.* Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. *Lancet* 2000 May 27;355(9218):1875-1881. [*PubMed:* 10866444.]

Patent Status: HHS Reference No. E-067-2011/0—Research Material. Patent protection is not being pursued for this technology.

Licensing Status: Research tool available for non-exclusive licensing.

Licensing Contact: Susan Ano, Ph.D.; 301-435-5515; anos@mail.nih.gov.

Glucocerebrosidase Activators as a Treatment for Gaucher Disease

Description of Invention: This technology is a collection of small molecule activators of a genetically defective version of the enzyme called glucocerebrosidase (GCase), which causes Gaucher disease. Gaucher disease is a rare disease affecting 1 in 40,000 babies born. Ashkenazi Jews of eastern European descent (about 1 in 800 live births) are at particular risk of carrying this genetic defect. It is caused by inherited genetic mutations in the gene that encodes GCase, which result in reduced activity of the enzyme. This enzyme is normally made and then transported to an organelle called a lysosome, which is dedicated to the degradation and disposal of molecules the cell no longer needs. GCase is responsible for the breakdown of a fatty material called glucocerebroside (or glucosylceramide). The accumulation of this lipid occurs inside specific cells called macrophages and macrophage-derived cells. The disease has been categorized into three types: neuronopathic (types 2, 3) and non-neuronopathic (type 1) with mild to severe symptoms that can appear at anytime from infancy to adulthood. Clinical manifestations can include an enlarged spleen and liver, anemia, decreased platelets, bone disease and neurodegeneration, with varying severity depending on the type of disease and time of diagnosis. The deficient GCase activity has been attributed to insufficient GCase enzyme in the lysosome. After production in the endoplasmic reticulum (ER), defective GCase does not fold properly and is therefore degraded in the ER and not transported to the lysosome where it would hydrolyze glucocerebroside. The small molecule activators may act by increasing the concentration of GCase that reaches the lysosome by facilitating the proper folding of GCase so that it can be released from the ER and transported to lysosomes. Thus, these small molecules could be acting like "chaperones," because they facilitate proper folding which results in some active enzyme. Prior failed attempts to use small molecule chaperones to improve GCase folding and transport were made with inhibitors of GCase, which ironically properly folded active GCase that was subsequently transported to the lysosome, but the molecule also inhibited the GCase so that it could not break down glucocerebroside. On the other hand, these proposed small molecules were

screened for their ability to activate defective GCase in the presence of a fluorogenic mimic of glucocerebroside, and their ability to facilitate translocation of defective GCase to lysosomes as well. This creates the opportunity to induce proper folding, while avoiding inhibition of enzyme function.

Application: Treatment of Gaucher Disease.

Development Status: Early development.

Inventors: Juan Marugan, Noel T. Southall, Ehud M. Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek (NHGRI.)

Related Publications: None.

Patent Status: U.S. Provisional Application No. 61/420,946, filed December 8, 2010, (HHS Reference No. E-257-2010/0-US-01.)

Licensing Status: Available for licensing.

Licensing Contact: Steve Standley, PhD; 301-435-4074; sstand@od.nih.gov.

A Novel Strategy for Development of an Effective HIV/AIDS Vaccine

Description of Invention: The invention offered for licensing and commercial development relates to the field of HIV/AIDS Vaccines. More specifically, the invention describes a novel strategy that can be useful in effective vaccination and treatment of HIV/AIDS infected persons. In this strategy (called 'trigger-and-neutralize' strategy) the infected subject is primed with HIV trimeric gp 120 immunogen to induce the production of CD4i (CD4-induced) antibodies. The patient is then treated with a compound that stabilizes the 'open' conformation of the gp120 of the HIV virus, at which conformation the gp120 epitope is better exposed and effectively neutralized by the CD4i antibodies.

Applications: Vaccination and treatment of HIV/AIDS infected patients.

Advantages: The unique strategy of eliciting CD4i antibodies *in vivo* and ensuring their neutralizing effect by stabilizing the gp120 open conformation, will provide more effective treatment compared to other published methods that utilize neutralizing antibodies to treat HIV/AIDS.

Development Status: The subject matter of the invention continues to be researched. Proof-of-principle of some of the aspects of the invention have been demonstrated.

Market: Although there are currently many commercial drugs available for treatment of HIV/AIDS, there still exists an urgent need to develop vaccines

against the disease. This need (no approved vaccine is available yet) is particularly important because of the resistance developed by many patients to commercial drugs and thus the need for the use of drug cocktails, as well as the severe side effects that many of the drugs exhibit. At present, the World Health Organization estimates that over 30 million people are infected with HIV and that over 25 million individuals have died from AIDS-related illnesses. The potential market for HIV vaccines is therefore huge and thus this invention may be commercially attractive for vaccine and drug manufacturers.

Inventors: Sriram Subramaniam (NCI.)

Relevant Publications:

1. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. *Nature*. 2008 Sep 4;455(7209):109-113. [PubMed: 18668044.]
2. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, M. de la Cruz MJ, Bess JW, Nandwani R, Hoxie JA, Lifson JD, Milne JL, Subramaniam S. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain dependent variation in quaternary structure. *PLoS Pathog*. 2010 Dec 23;6(12):e1001249. [PubMed: 21203482.]
3. Felts RL, Narayan K, Estes JD, Shi D, Trubey CM, Fu J, Hartnell LM, Ruthel GT, Schneider DK, Nagashima K, Bess JW Jr, Bavari S, Lowekamp BC, Bliss D, Lifson JD, Subramaniam S. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T-cells. *Proc Natl Acad Sci U S A*. 2010 Jul 27;107(30):13336-13341. [PubMed: 20624966.]

Patent Status: U.S. Provisional Application No. 61/356,326 filed 18 Jun 2010 (HHS Reference No. E-201-2010/0-US-01), entitled "Immunogenic Compositions Derived from Structural Alteration of HIV Envelope Proteins."

Licensing Status: Available for licensing and commercial development.

Licensing Contacts:

- Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
- John Stansberry, PhD; 301-435-5236; js852e@nih.gov.

Collaborative Research Opportunity: The Center for Cancer Research, NCI/NIH is seeking statements of capability or interest from parties interested in collaborative research to further develop, produce, evaluate, or commercialize trimeric gp120 immunogens. Please contact John Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for more information.

Epoxy-guaiane Cancer Inhibitors: New Class of Natural Products Isolated From the African Plant *Phyllanthus englerii*

Description of Invention: The present invention involves the observation of renal selective inhibitory activity by the extracts of the African plant *Phyllanthus englerii*. Bioassay-guided fractionation of the purified extracts revealed a series of novel chemical entities which are named Englerin A-F. The englerins and their derivatives are useful in the treatment of a number of cancers, particularly renal cancer. The englerins exhibit selective and potent renal cell inhibitory activity *in vitro*.

These compounds are recoverable in reasonable yield from natural product extracts and are considered to be reasonably tractable for synthetic chemistry schemes. Sufficient supply of several analogs had been extracted from repository samples for identification and initial biological characterization. Subsequent five-dose testing in the NCI60 screening panel indicated and confirmed impressive renal-selective activity.

Applications: The new chemical entities can be potential cancer therapeutics, especially for renal cancer.

Advantages:

- There is reasonable yield and recovery of the compounds from the natural product extracts.

- The synthetic chemistry schemes for synthesis of these compounds are considered to be reasonably tractable.

Development Status: Proof of concept *in vitro* studies have been completed and further *in vitro* and *in vivo* animal model studies are ongoing.

Inventors: John A. Beutler *et al.* (NCI)

Relevant Publication: S.

Sutthivaiyakit *et al.* A novel 29-nor-3,4-seco-friedelane triterpene and a new guaiane sesquiterpene from the roots of *Phyllanthus oxyphyllus*. *Tetrahedron* 2003 Dec 8; 59(50):9991-9995.

Patent Status: U.S. Patent Application No. 12/811,245 filed 29 Jul 2010 (HHS Reference No. E-064-2008/2-US-06) and related international filings.

Licensing Status: Available for licensing.

Licensing Contact: Surekha Vathyam, PhD; 301-435-4076; vathyams@mail.nih.gov.

Collaborative Research Opportunity: The National Cancer Institute Molecular Targets Development Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize epoxy-guaiane cancer inhibitors. Please contact John D. Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for more information.

Imidazoacridones With Anti-Tumor Activity

Description of Invention: The present invention relates to novel bifunctional molecules with potent and selective activity against colon, liver and pancreatic tumors. Compounds have low animal toxicity, excellent PK/PD characteristics and proved to be very effective in several preclinical animal models of cancer. Extensive mechanistic studies have demonstrated that compounds inhibit tumor growth through a novel mechanism. These agents are composed of an imidazoacridone moiety linked by a nitrogen containing aliphatic chain of various length and rigidity to another aromatic ring system capable of intercalation to DNA.

Previous studies on related symmetrical bis-imidazoacridones revealed that only one planar imidazoacridone moiety intercalates into DNA. The second aromatic moiety, which is crucial for biological activity, along with the linker resides in DNA minor groove, and is believed to interact with DNA-binding proteins (most likely, transcription factors and/or repair proteins). The symmetrical bis-imidazoacridones arrest the growth of sensitive cancers (especially colon cancers) but do not kill the tumors. It was hypothesized that the growth arrest was due to the inability of the affected tumor cells to repair DNA damage caused by the compounds. Remarkably, bis-imidazoacridones are very well tolerated, are very tissue selective and do not appear to damage normal tissues.

Since the binding of the symmetrical bis-imidazoacridones to DNA was unsymmetrical, the inventors have developed unsymmetrical compounds in which one imidazoacridone moieties was replaced by other intercalating groups, with the expectation that this would enhance biological activity while retaining the remarkable tissue selectivity and low systemic toxicity. The new compounds contain intercalating moieties such as 3-chloro-7-methoxyacridine or naphthalimide along with the original imidazoacridones.

These new compounds, especially those containing naphthalimide moiety, are extremely cytotoxic against a variety of tumor cells in vitro (IC₅₀ at low nanomolar range) and kill tumor cells by inducing apoptosis. In vivo, in nude mice xenografted with human tumors, the compounds significantly inhibited the growth of such tumors as colon tumor HCT116 and Colo205 as well as pancreatic tumors (lines 6.03 and 10.05 freshly established from a patient).

These compounds are extremely potent agents against hepatocellular carcinoma as evidenced by their ability to eradicate liver cancer in an orthotopic liver cancer model in rats. Remarkably, no toxicity was observed at the therapeutic doses. These are among the most potent agents known against cancers of the GI tract and appear to be tolerated very well.

Inventors: Wieslaw M. Cholody *et al.* (NCI)

Patent Status:

- U.S. Patent 6,664,263 issued 16 Dec 2003 (HHS Reference No. E-289-1999/0-US-07) and related international patents/patent applications.

- U.S. Patent 6,541,483 issued 01 Apr 2003 (HHS Reference No. E-065-1996/2-US-25) and related international patents/patent applications.

Licensing Status: Available for licensing.

Licensing Contact: Betty B. Tong, PhD; 301-594-6565; tongb@mail.nih.gov.

Collaborative Research Opportunity: The National Cancer Institute, Center for Cancer Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize imidazoacridones as therapeutic agents for cancer treatment. Please contact John Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for more information.

Dated: April 29, 2011.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011-11055 Filed 5-4-11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Child Health and Human Development Council.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Child Health and Human Development Council.

Date: June 2, 2011.

Open: 8 a.m. to 12:20 p.m.

Agenda: (1) A report by the Director, NICHD; (2) Report of the Subcommittee on Planning and Policy; (3) NICHD Scientific Visioning update; and other business of the Council.

Place: National Institutes of Health, Building 31, 31 Center Drive, C-Wing, Conference Room 6, Bethesda, MD 20892.

Closed: 12:20 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: National Institutes of Health, Building 31, 31 Center Drive, C-Wing, Conference Room 6, Bethesda, MD 20892.

Contact Person: Yvonne T. Maddox, PhD, Deputy Director, National Institute of Child Health, and Human Development, NIH, 9000 Rockville Pike MSC 7510, Building 31, Room 2A03, Bethesda, MD 20892, (301) 496-1848.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxis, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <http://www.nichd.nih.gov/about/nachhd.htm>, where an agenda and any additional information for the meeting will be posted when available.

In order to facilitate public attendance at the open session of Council, reserve seating will be made available to the first five individuals reserving seats in the main meeting room, Conference Room 6. Please contact Ms. Lisa Kaeser, Program and Public Liaison Office, NICHD, at 301-496-0536 to make your reservation. Additional seating will be available in the meeting overflow rooms, Conference Rooms 7 and 8. Individuals will also be able to view the meeting via NIH Videocast. Please go to the following link for Videocast access